Requirement of Ca2+ and PKCδ for Janus Kinase 2 activation by angiotensin II: Involvement of PYK2

Molecular Endocrinology

Volumn 16, Issue 2, 2002, Pages 367-377

  Frank, Gerald D ^a   Saito, Shuichi ^a   Motley, Evangeline D ^b   Sasaki, Terukatsu ^c   Ohba, Motoi ^d   Kuroki, Toshio ^d   Inagami, Tadashi ^a   Eguchi, Satoru ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; CALCIUM ION; DIACYLGLYCEROL; JANUS KINASE; JANUS KINASE 2; PHOSPHATIDYLINOSITOL; PROTEIN KINASE C; PROTEIN KINASE C DELTA; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRANSCRIPTION INITIATION; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; CALCIUM; CELLS, CULTURED; ENZYME ACTIVATION; FOCAL ADHESION KINASE 2; IMMUNOHISTOCHEMISTRY; ISOENZYMES; JANUS KINASE 2; MUSCLE, SMOOTH, VASCULAR; PHOSPHOLIPASE C; PHOSPHOLIPID ETHERS; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTEIN KINASE C; PROTEIN KINASE C-DELTA; PROTEIN TRANSPORT; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; SIGNAL TRANSDUCTION; TRANSFECTION;

ANIMALIA; JANUS;

EID: 0036162480     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.16.2.367     Document Type: Article

References (59)

1. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases
2. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells
3. Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension
4. Angiotensin receptors and their antagonists
5. The multiple actions of angiotensin II in atherosclerosis
6. Angiotensin II signaling in vascular smooth muscle. New concepts
7. Angiotensin II signal transduction in vascular smooth muscle: Pathways activated by specific tyrosine kinases
8. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase
9. Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells
10. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells
11. Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on c-Src in vascular smooth muscle cells
12. Regulation of a calcium-dependent tyrosine kinase in vascular smooth muscle cells by angiotensin II and platelet-derived growth factor. Dependence on calcium and the actin cytoskeleton
13. Calcium- and protein kinase C-dependent activation of the tyrosine kinase PYK2 by angiotensin II in vascular smooth muscle
14. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor
15. Cytokines and JAK-STAT signaling
16. Janus kinases: Components of multiple signaling pathways
17. Biphasic activation of the JAK/STAT pathway by angiotensin II in rat cardiomyocytes
18. Angiotensin II signalling events mediated by tyrosine phosphorylation
19. Role of Janus kinase/signal transducer and activator of transcription and mitogen-activated protein kinase cascades in angiotensin II- and platelet-derived growth factor-induced vascular smooth muscle cell proliferation
20. Molecular mechanisms of angiotensin II in modulating cardiac function: Intracardiac effects and signal transduction pathways
21. Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor
22. Janus kinase 2 (Jak2) must be catalytically active to associate with the AT1 receptor in response to angiotensin II
23. Phosphorylation of JAK2 in thrombin-stimulated human platelets
24. Serpentine receptors and STAT activation: More than one way to twin a STAT
25. Involvement of JAK/STAT (Janus kinase/signal transducer and activator of transcription) in the thyrotropin signaling pathway
26. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway
27. Hyperglycemia enhances angiotensin II-induced janus-activated kinase/STAT signaling in vascular smooth muscle cells
28. Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-OCH3: Involvement of the Fas receptor/ligand system
29. Rottlerin, a novel protein kinase inhibitor
30. Partial purification of type eta protein kinase C from brain: Separation from other protein kinase C isozymes and characterization
31. Involvement of PYK2 in angiotensin II signaling of vascular smooth muscle cells
32. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation
33. PYK2/CAKβ represents a redox-sensitive tyrosine kinase in vascular smooth muscle cells
34. Unique regulation of c-Jun N-terminal kinase by PYK2/CAK-β in angiotensin II-stimulated vascular smooth muscle cells
35. Angiotensin II-induced tyrosine phosphorylation of signal transducers and activators of transcription 1 is regulated by Janus-activated kinase 2 and Fyn kinases and mitogen-activated protein kinase phosphatase 1
36. Angiotensin II-stimulated induction of sis-inducing factor is mediated by pertussis toxin-insensitive G(q) proteins in cardiac myocytes
37. Tyrosine kinase activation by the angiotensin II receptor in the absence of calcium signaling
38. Protein kinase Cδ inhibits the proliferation of vascular smooth muscle cells by suppressing G1 cyclin expression
39. Protein kinase Cδ
40. Interaction between protein kinase Cδ and the c-Abl tyrosine kinase in the cellular response to oxidative stress
41. Activation of MAP kinases by angiotensin II in vascular smooth muscle cells: Metalloprotease-dependent EGF receptor activation is required for ERK and p38 MAP kinase, but not for JNK
42. Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-γ, but not IFN-α, signaling
43. A catalytically active Jak2 is required for the angiotensin II-dependent activation of Fyn
44. The angiotensin II-dependent association of Jak2 and c-Src requires the N-terminus of Jak2 and the SH2 domain of c-Src
45. Regulation of calcium-sensitive tyrosine kinase Pyk2 by angiotensin II in endothelial cells. Roles of Yes tyrosine kinase and tyrosine phosphatase SHP-2
46. Fyn and JAK2 mediate Ras activation by reactive oxygen species
47. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction
48. Activation of the JAK-STAT pathway by reactive oxygen species
49. 2
50. N-Acetylcysteine inhibits angiotensin II-mediated activation of extracellular signal-regulated kinase and epidermal growth factor receptor
51. Involvement of reactive oxygen species in the activation of tyrosine kinase and extracellular signal-regulated kinase by angiotensin II
52. Role of angiotensin II in activation of the JAK/STAT pathway induced by acute pressure overload in the rat heart
53. Role of the JAK/STAT pathway in rat carotid artery remodeling after vascular injury
54. 2+/calmodulin-sensitive tyrosine kinase
55. Phosphorylation of Hic-5 at tyrosine 60 by CAKβ and Fyn
56. Induction of differentiation in normal human keratinocytes by adenovirus-mediated introduction of the η and δ isoforms of protein kinase C
57. Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser411 in vascular smooth muscle cells: Possible requirement of EGF receptor, RAS, ERK, and AKT
58. Effects of short chain fatty acids on a new human colon carcinoma cell line (LIM1215)
59. The catalytic domain of protein kinase Cδ confers protection from down-regulation induced by bryostatin 1